Retinoids in Cutaneous T Cell Lymphomas
Published on Sunday, 30 June 2013
Abstract
Sixteen patients – 12 with cutaneous T cell lymphoma (CTCL), 1 with Sézary syndrome, 1 with actinic reticuloid, and 2 with parapsoriasis variegata – were treated with either a new, potent arotinoid alone or with combined etretinate (Tigason®) and PUVA therapy (Re-PUVA).
92% of all patients showed a minor up to a distinct response of their skin lesions within 12.6 ± 7.4 weeks. More than 50% of the skin lesions cleared in 67% of the patients.
After discontinuation of the retinoid therapy, relapses occurred in all cases within 3–10 weeks. There was no difference between the therapeutic efficacy of arotinoid alone and the Re-PUVA regimen, but the latter was less toxic.